In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 2, 1998, Pages 91-98

  Kano, Yasuhiko ^a   Akutsu, Miyuki ^a   Tsunoda, Saburo ^a   Mori, Kovoshi ^a   Suzuki, Kenichi ^a   Adachi, Ken Ichi ^b  

^a TOCHIGI CANCER CENTER   (Japan)

^b NIPPON KAYAKU CO LTD   (Japan)

Author keywords

Irinotecan; Isobologram; Paclitaxel; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN; PACLITAXEL;

ARTICLE; ASSAY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0031832323     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050790     Document Type: Article

References (41)

1. Akutsu M, Kano Y, Tsunoda S, Suzuki K, Yazawa Y, Miura Y (1995) Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro. Eur J Cancer 31A: 2341
2. Buzdar AU, Holmes FA, Hortobagyi GN (1995) Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. Semin Oncol 22 [Suppl 6]: 101
3. Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517
4. Del Bino G, Lassota P, Darzynkiewicz Z (1991) The S-phase cytotoxicity of camptothecin. Exp Cell Res 193: 27
5. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS (1987) Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 71: 1171
6. Gottlieb JA, Luce JK (1972) Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56: 103
7. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47:331
8. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797
9. Hsiang Y-H, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein linked DNA breaks via mammalian DNA-topoisomerase I. J Biol Chem 260: 14873
10. Jekunen A, Christen R, Shalinsky D, Howell SB (1994) Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69: 299
11. Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M (1997) In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer 75: 869
12. Kano Y, Sakamoto S, Kakahara T, Akutsu M, Inoue Y, Miura Y (1991) In vitro effects of amsacrine in combination with other anti-cancer agents. Leukemia Res 15: 1059
13. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50: 604
14. Kano Y, Akutsu M, Tsunoda S, Suzuki K, Yazawa Y (1995) In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Cancer Chemother Pharmacol 37: 525
15. Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y, Adachi K (1996) Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 74: 704
16. Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK (1996) Cytotoxic effects of topotecan combined with various anti-cancer agents in human cancer cell lines. J Natl Cancer Inst 88: 734
17. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187
18. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944
19. Liebmann J, Fisher J, Teage D, Cook JA (1994) Sequence dependence of paclitaxel combined with cisplatin or alkylators in human cancer cells. Oncol Res 6: 25
20. Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hallis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL (1995) Phase I study of paclitaxel and topotecan in patients with advanced tumors: a Cancer and Leukemia Group B Study. J Clin Oncol 13: 2230
21. Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3: 285
22. Lopes NM, Adams EG, Pitts TW, Bhuyan BK (1993) Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32: 235
23. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: a new derivative of camptothecin for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225
24. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S (1992) Phase 1 study of irinotecan in combination with cis-platin for advanced non-small cell lung cancer. J Clin Oncol 10: 1775
25. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273
26. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95
27. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN (1993) Phase II study of taxol in untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85: 384
28. Nagata H (1987) Flow cytometric analysis of the effect of an antitumor alkaloid, camptothecin on cell cycle progression of KB cell. J Aichi Med Univ Assoc 15: 683
29. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M (1990) An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907
30. O'Reilly S, Fleming GF, Baker SD, Walczak JR, Bookman MA, McGuire WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK (1997) Phase I trial and pharmacologic trial of sequence of paclitaxel and topotecan in previously treated ovarian epitherial malignancies: a Gynecological Oncology Group Study. J Clin Oncol 15: 177
31. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW (1988) Microtubule changes and cytotoxicity in leukemia cell lines treated with taxol. Cancer Res 48: 4093
32. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornblath DR, Hendrich CB, Donehower RC (1991) Sequence of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692
33. Sasaki Y, Morita M, Miya T, Shinkai T, Eguchi K, Tamura T, Ohe Y, Saijo N (1992) Pharmacokinetic (PK) and pharmacodynamic (PD) analysis of CPT-11 and its active metabolite of SN-38 (abstract). Proc Am Soc Clin Oncol 11: 111
34. Schilf PB, Horwitz SB (1981) Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochemistry 20: 3247
35. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N (1993) Phase II study of CPT-11, a new camptothecin derivative, in patients with metastatic colorectal cancer. CPT-11 gastrointestinal cancer study group. J Clin Oncol 11: 909
36. Steel GG (1993) Combination of radiotherapy and chemotherapy. In: Steel GG (ed) Basic clinical radiobiology. Edward Arnold, London, p 151
37. Steel GG, Peckham MJ (1993) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85
38. Taguchi T, Wakui A, Hasegawa K, Niitani H, Furue H. Ohta K, Hattori T (1990) Phase I clinical study of CPT-11 (in Japanese). Gan To Kagaku Ryoho 17: 115
39. Takeuchi S, Noda K, Yakushiji M (1992) and CPT-11 Study Group of Gynecological Malignancy. Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma (abstract). Proc Am Soc Clin Oncol 11: 224
40. Webb JL (1963) Effect of more than one inhibitor. In: Enzymes and metabolic inhibitors, vol 1. Academic Press, New York, p 66
41. Yeh YA, Olah E, Wendel JJ, Sledge GW Jr, Weber G (1994) Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: schedule-dependence. Life Sci 54: 431